#RBQMLive
RBQM 2023 On-Demand
Day One Sessions
Day Two Sessions
Keynote: The Global Transformation of RBQM - Research Study Findings from a 2023 Survey and Executive Roundtable Discussions
Speaker:
Ken Getz, Executive Director and Professor, Tufts Center for the Study of Drug Development
Ken Getz, Executive Director and Professor, Tufts Center for the Study of Drug Development
The ABC’s of ICH E6 (R3): Understanding the Guidance Updates
Speaker: Dave Nickerson, Head of Clinical Quality Management, EMD Serono
Mastering RBQM During the Design & Planning Phases Critical to Quality Factors
Speaker: Jonathan Rowe, Principal – Head of R&D Quality, Operations & Risk Management, ZS Associates
Keynote Panel Discussion: The RBQM Journey…
Panelists: Karen McCarthy Schau, Sr. Director, Clinical Data Management, Vertex / Lesley Lardino, Senior Director, Data Management, Astellas/ Cris McDavid, Director, Clinical Operations, RBQM, Parexel
The Evolution of QTLs in Light of ICH E6(R3) – Recommendations from Industry Experts
Panelists: Marcin Makowski, Head of Centralized Monitoring and Data Analytics at GSK / Linda Sullivan, Senior Fellow, Tufts Center for the Study of Drug Development / Marion Wolfs, Global Head Risk Management and Central Monitoring, Janssen
Understanding the RBQM Process & Documentation Phase Central Monitoring & Risk Based Study Execution
Panelists: Neshad Sharma, Senior Manager, CD&O Support & Enhancement, Process Excellence, Bayer / Scott Litrakis, Executive Director, Clinical Compliance & Risk Management, Bristol-Myer Squibb / Brian Barnes, Director, Risk Management Strategy – Process Excellence & Oversight, BioNTech